Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study)

The KNOG-1101 study, a phase II trial conducted in South Korea, assessed the impact of adding temozolomide to radiotherapy on the health-related quality of life (HRQoL) of 90 patients with grade III gliomas. The study found that temozolomide improved 2-year progression-free survival without negatively affecting HRQoL. Emotional functioning, fatigue, nausea, and other symptoms showed no significant differences between the treatment group and the control group. Although there were initial differences in global health status and cognitive functioning, these were not statistically significant. The study concluded that temozolomide provided a long-term net clinical benefit for patients with anaplastic gliomas, supporting its use in treatment regimens.